New inhaled drug RCS-21 put to first safety test in humans
NCT ID NCT06752122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a single inhaled dose of RCS-21 is safe and tolerable in 24 healthy volunteers aged 18 to 64. Participants receive either the drug or a placebo and are closely monitored for side effects and how the drug moves through the body. The study does not aim to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
RECRUITINGHanover, 30625, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Can a simple calcium tablet help prevent postpartum bleeding?
- Brain waves under pressure: can light uncover the signature of mental work?